E-Newsletter | October 2025
Spotlight on ASCO 2025
Alliance Webinar Showcases Five Best of ASCO 2025 Abstracts
Alliance recently presented a special webinar highlighting five of the top-rated abstracts from its investigators featured at the 2025 ASCO Annual Meeting. This year, Alliance presented more than 20 abstracts at ASCO, showcasing the breadth and quality of its research.The webinar showcased cutting-edge research and innovative findings across a range of cancer types, reflecting the depth and impact of Alliance-led studies. Attendees heard directly from the lead investigators, who shared valuable insights into the latest advances in clinical trials and oncology care.
The webinar was recorded and can be watched online.
Panelists included:
Dan Zandberg, MD, UPMC Hillman Cancer Center: Dr. Zanberg presented the results of Alliance A091802: A phase II randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma.
Sara Char, MD, Dana Farber Cancer Institute: Dr. Char discussed the results of CALGB/SWOG (Alliance) 80702: Association between empirical dietary inflammatory pattern and survival in patients with stage III colon cancer.
Frank Sinicrope, MD, Mayo Clinic: Dr. Sinicrope presented the findings of Alliance A021502-ATOMIC: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair.
Ellen Smith, PhD, University of Alabama School of Nursing: Dr. Smith reviewed the findings of Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled phase II study.
Tian Zhang, MD, University of Texas Southwestern Medical Center: Dr. Zhang discussed Alliance A031704: Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma treated on the phase III PDIGREE (A031704) trial: results from Step 1 analysis.
Read more articles in this issue:
